{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:34:04Z","timestamp":1790685244214,"version":"4.1.0"},"reference-count":117,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Eton College and The Wallitt Foundation"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Today, there is continued, and in some cases growing, availability of not only psychoactive substances, including treatments for mental health disorders such as cognitive enhancers, which can enhance or restore brain function, but also \u2018recreational\u2019 drugs such as novel psychoactive substances (NPS). The use of psychoactive drugs has both benefits and risks: whilst new drugs to treat cognitive symptoms in neuropsychiatric or neurodegenerative disorders could have great benefits for many patient groups, the increasing ease of accessibility to recreational NPS and the increasing lifestyle use of cognitive enhancers by healthy people means that the effective management of psychoactive substances will be an issue of increasing importance. Clearly, the potential benefits of cognitive enhancers are large and increasingly relevant, particularly as the population ages, and for this reason, we should continue to devote resources to the development of cognitive enhancers as treatments for neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease, attention deficit hyperactivity disorder and schizophrenia. However, the increasing use of cognitive enhancers by healthy individuals raises safety, ethical and regulatory concerns, which should not be ignored. Similarly, understanding the short\u2010 and long\u2010term consequences of the use of NPS, as well as better understanding the motivations and profiles of users could promote more effective prevention and harm reduction measures.<\/jats:p>\n                    <jats:sec>\n                      <jats:title>Linked Articles<\/jats:title>\n                      <jats:p>\n                        This article is part of a themed section on Pharmacology of Cognition: a Panacea for Neuropsychiatric Disease? To view the other articles in this section visit\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bph.v174.19\/issuetoc\">http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bph.v174.19\/issuetoc<\/jats:ext-link>\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1111\/bph.13813","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T19:07:37Z","timestamp":1492715257000},"page":"3257-3267","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure"],"prefix":"10.1111","volume":"174","author":[{"given":"L\u2010S Camilla","family":"d'Angelo","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioural and Clinical Neuroscience Institute University of Cambridge  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Savulich","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioural and Clinical Neuroscience Institute University of Cambridge  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0521-5735","authenticated-orcid":false,"given":"Barbara J","family":"Sahakian","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioural and Clinical Neuroscience Institute University of Cambridge  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,12]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Academy of Medical Sciences(2012).Human enhancement and the future of work. Report from a joint workshop hosted by the Academy of Medical Sciences the British Academy the Royal Academy of Engineering and the Royal Society (ed. Academy of Medical Sciences). London UK. Available at:https:\/\/www.acmedsci.ac.uk\/viewFile\/publicationDownloads\/135228646747.pdf(accessed 5\/1\/17)."},{"key":"e_1_2_8_3_1","unstructured":"Academy of Medical Sciences(2008).Brain science addiction and drugs. Academy of Medical Sciences London UK. Available at:https:\/\/www.acmedsci.ac.uk\/viewFile\/524414fc8746a.pdf(accessed 5\/1\/17)."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13348"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13350"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13354"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-1912-x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.28.061604.135709"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.07.028"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/4551057a"},{"key":"e_1_2_8_11_1","unstructured":"BourneA ReidD HicksonF Torres RuedaS WeatherburnP(2014)The Chemsex study: drug use in sexual settings among gay & bisexual men in Lambeth Southwark & Lewisham. London: Sigma Research. Available at:https:\/\/www.lambeth.gov.uk\/sites\/default\/files\/ssh\u2010chemsex\u2010study\u2010final\u2010main\u2010report.pdf"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13040"},{"key":"e_1_2_8_13_1","first-page":"777","article-title":"Modafinil's effects on simulator performance and mood in pilots during 37 h without sleep","volume":"75","author":"Caldwell JA","year":"2004","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_8_14_1","unstructured":"Care Quality Commission(2016).The safer management of controlled drugs: annual report 2015. Available at:http:\/\/www.cqc.org.uk\/sites\/default\/files\/20160714_controlleddrugs2015_report.pdf"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.08.005"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3266-08.2009"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9280.t01-1-01430"},{"key":"e_1_2_8_18_1","unstructured":"CorbynZ(2015).Get ahead in Silicon Valley: take nootropic brain drugs. The Guardian. Available at:https:\/\/www.theguardian.com\/technology\/2015\/jul\/11\/hack\u2010yourself\u2010nootropic\u2010drugs\u2010upgrade\u2010mind(accessed 5\/1\/17)."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2016.28"},{"key":"e_1_2_8_20_1","unstructured":"DaviesM(2015). 'Smart drugs' really DO work: pills taken by a fifth of university students found to improve memory and learning \u2010 raising 'serious ethical questions'. Mail Online. Available at:http:\/\/www.dailymail.co.uk\/health\/article\u20103204567\/Smart\u2010drugs\u2010really\u2010work\u2010Pills\u2010taken\u2010fifth\u2010university\u2010students\u2010improve\u2010memory\u2010learning\u2010raising\u2010ethical\u2010questions.html(accessed 5\/1\/17)."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt263"},{"key":"e_1_2_8_22_1","unstructured":"DunnJ(2016).Survey aims for first look at use of \u201csmart drugs\u201d in finance industry. Finsia. Available at:http:\/\/finsia.com\/news\/news\u2010article\/2016\/09\/15\/survey\u2010aims\u2010for\u2010first\u2010look\u2010at\u2010use\u2010of\u2010smart\u2010drugs\u2010in\u2010finance\u2010industry(accessed 5\/1\/17)."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050892"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobeha.2015.01.005"},{"key":"e_1_2_8_25_1","unstructured":"European Commission(2014).Flash eurobarometer 401. Young people and drugs. Available at:http:\/\/ec.europa.eu\/public_opinion\/flash\/fl_401_en.pdf(accessed 5\/1\/17)."},{"key":"e_1_2_8_26_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction(2016).European drug report 2016: trends and developments publications office of the European Union Luxembourg. Available at:http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2637\/TDAT16001ENN.pdf(accessed 5\/1\/17)."},{"key":"e_1_2_8_27_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction(2015a).European drug report 2016: trends and developments publications office of the European Union Luxembourg. Available at:http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/974\/TDAT15001ENN.pdf(accessed 5\/1\/17)."},{"key":"e_1_2_8_28_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction(2015b).New psychoactive substances in Europe. An update from the EU Early Warning System (March 2015) Publications Office of the European Union Luxembourg Available at:http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/65\/TD0415135ENN.pdf"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2011.00060"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2015.07.006"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-102"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/00207459808986412"},{"key":"e_1_2_8_33_1","unstructured":"Global Drug Survey(2016).Global drug survey 2016. Available at:https:\/\/www.globaldrugsurvey.com\/wp\u2010content\/uploads\/2016\/06\/TASTER\u2010KEY\u2010FINDINGS\u2010FROM\u2010GDS2016.pdf(accessed 5\/1\/17)."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/6365"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.10.018"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0026269"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12703"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6939-15-23"},{"key":"e_1_2_8_39_1","unstructured":"Home Office(2016).Drug misuse: findings from the 2015\/16 crime survey for England and Wales. Second Edition. Available at:https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/564760\/drug\u2010misuse\u20101516.pdf(accessed 5\/1\/17)."},{"key":"e_1_2_8_40_1","unstructured":"Home Office(2015).Drug misuse: findings from the 2014\/15 crime survey for England and Wales. Second Edition. Available at:https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/462885\/drug\u2010misuse\u20101415.pdf"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2013.00198"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0498-460"},{"key":"e_1_2_8_43_1","unstructured":"JohnstonLD O'MalleyPM MiechRA BachmanJG SchulenbergJE(2016).Monitoring the Future national survey results on drug use 1975\u20132015: overview key findings on adolescent drug use. Available at:http:\/\/www.monitoringthefuture.org\/pubs\/monographs\/mtf\u2010overview2015.pdf(accessed 5\/1\/17)."},{"key":"e_1_2_8_44_1","unstructured":"JohnstonLD O'MalleyPM BachmanJG SchulenbergJE MiechRA(2014).Monitoring the future national survey results on drug use 1975\u20132013: Volume I secondary school students. Available at:http:\/\/www.monitoringthefuture.org\/pubs\/monographs\/mtf\u2010vol1_2013.pdf"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116632375"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13081075"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tics.2010.05.002"},{"key":"e_1_2_8_48_1","unstructured":"KordtM(2015).DAK\u2010Gesundheitsreport 2015. Berlin. Available at:https:\/\/www.dak.de\/dakonline\/live\/dak\/download\/Vollstaendiger_bundesweiter_Gesundheitsreport_2015\u20101585948.pdf(accessed 5\/1\/17)."},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.18422"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/452674a"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077967"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.15.2.123"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000079"},{"key":"e_1_2_8_54_1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.12740\/PP\/18603","article-title":"Prevalence, reasons, and forms of use of legal highs by internet\u2010based survey participants","volume":"47","author":"Mazurkiewicz MR","year":"2013","journal-title":"Psychiatr Pol"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2010.11.001"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1206820109"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2016.00153"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301534"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.07.009"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1926-3"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/0265203021000007840"},{"key":"e_1_2_8_62_1","unstructured":"NicholsonPJ MayhoG SharpC(2015).Cognitive enhancing drugs and the workplace. BMA. London. Available at:https:\/\/www.bma.org.uk\/advice\/employment\/occupational\u2010health\/cognitive\u2010enhancing\u2010drugs(accessed 5\/1\/17)."},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.3109\/09687637.2014.989959"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/hipo.20157"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1089\/cyber.2014.0486"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.01.044"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.08.028"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2312"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028416"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobeha.2015.05.004"},{"key":"e_1_2_8_71_1","unstructured":"Prisons and probations ombudsman for England and Wales. (2015).New psychoactive substances. Learning lessons bulletin: Fatal incident investigations issue 9. Available at:http:\/\/www.ppo.gov.uk\/wp\u2010content\/uploads\/2015\/07\/LLB_FII\u2010Issue\u20109_NPS_Final.pdf#view=FitH(accessed 5\/1\/17)."},{"key":"e_1_2_8_72_1","unstructured":"Psychoactive Substances Act2016. Available at:http:\/\/www.legislation.gov.uk\/ukpga\/2016\/2\/pdfs\/ukpga_20160002_en.pdf(accessed 5\/1\/17)."},{"key":"e_1_2_8_73_1","unstructured":"Public Health England(2016).Shooting up infections among people who injected drugs in the UK 2015. An update: November 2016 Available at:https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/567231\/Shooting_Up_2016_Update.pdf"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2010.02.009"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2010.04.002"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(79)90157-6"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60248-3"},{"key":"e_1_2_8_78_1","unstructured":"Royal Society. (2011).Brain waves module 2: neuroscience: implications for education and lifelong learning. Royal Society London UK. Available at:https:\/\/royalsociety.org\/~\/media\/Royal_Society_Content\/policy\/publications\/2011\/4294975733.pdf(accessed 5\/1\/17)."},{"key":"e_1_2_8_79_1","article-title":"The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people","volume":"370","author":"Sahakian BJ","year":"2015","journal-title":"Philos Trans R Soc B Biol Sci B"},{"key":"e_1_2_8_80_1","volume-title":"Games for the Brain","author":"Sahakian BJ","year":"2017"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(15)00004-8"},{"key":"e_1_2_8_82_1","unstructured":"SahakianBJ(2014).Record seizure of smart drugs including one untested in humans shows growing market. The Conversation. Available at:https:\/\/theconversation.com\/record\u2010seizure\u2010of\u2010smart\u2010drugs\u2010including\u2010one\u2010untested\u2010in\u2010humans\u2010shows\u2010growing\u2010market\u201033563(accessed 5\/1\/17)."},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244644"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-9877(77)90065-2"},{"key":"e_1_2_8_85_1","volume-title":"Bad Moves: How Decision Making Goes Wrong, and the Ethics of Smart Drugs","author":"Sahakian B","year":"2013"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/4501157a"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1080\/02701367.1999.10608030"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.03.005"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2635"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.457"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnsys.2015.00010"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-2070-x"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20174"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.07.011"},{"key":"e_1_2_8_95_1","unstructured":"SerranoS(2015).Taking the 'smart drug' modafinil made me love work but hate people. Vice. Available at:https:\/\/www.vice.com\/en_uk\/article\/taking\u2010modafinil\u2010made\u2010me\u2010love\u2010work\u2010but\u2010hate\u2010everything\u2010else\u2010876(accessed 5\/1\/17)."},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105969"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0023825"},{"key":"e_1_2_8_98_1","unstructured":"SolonO(2016).Would you take LSD to give you a boost at work?WIRED takes a trip inside the world of microdosing. Wired. Available at:http:\/\/www.wired.co.uk\/article\/lsd\u2010microdosing\u2010drugs\u2010silicon\u2010valley(accessed 5\/1\/17)."},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2016.03.007"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1037"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3188-4"},{"key":"e_1_2_8_102_1","unstructured":"StephensonG RichardsonA(2014).New psychoactive substances in England. A review of the evidence. Home Office. Available at:https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/368587\/NPSevidenceReview.pdf(accessed 5\/1\/17)."},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3182306c99"},{"key":"e_1_2_8_104_1","unstructured":"TalbotM(2009).Brain gain. The underground world of \u201cneuroenhancing\u201d drugs. The New Yorker. Available at:http:\/\/www.newyorker.com\/magazine\/2009\/04\/27\/brain\u2010gain(accessed 5\/1\/17)."},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e31802eb7ea"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.10.1501"},{"key":"e_1_2_8_107_1","unstructured":"The Student Room(2016).New research reveals 1 in 10 students have taken study drugs. Available at:http:\/\/tsrmatters.com\/wp\u2010content\/uploads\/2013\/07\/New\u2010research\u2010reveals\u20101\u2010in\u201010\u2010students\u2010have\u2010taken\u2010study\u2010drugs.pdf(accessed 5\/1\/17)."},{"key":"e_1_2_8_108_1","doi-asserted-by":"crossref","unstructured":"United Nations Office on Drugs and Crime(2016).World drug report 2016. Available at:https:\/\/www.unodc.org\/doc\/wdr2016\/WORLD_DRUG_REPORT_2016_web.pdf(accessed 5\/1\/17).","DOI":"10.18356\/603a2a94-en"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2010.12.014"},{"key":"e_1_2_8_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1402309"},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1080\/21507740.2012.740141"},{"key":"e_1_2_8_112_1","doi-asserted-by":"crossref","unstructured":"Wenner MoyerM(2016).A safe drug to boost brainpower. Scientific American Mind 27(2). Available at:https:\/\/www.scientificamerican.com\/article\/a\u2010safe\u2010drug\u2010to\u2010boost\u2010brainpower\/(accessed 5\/1\/17).","DOI":"10.1038\/scientificamericanmind0316-16"},{"key":"e_1_2_8_113_1","first-page":"32","article-title":"Mechanism of action of agents used in attention\u2010deficit\/hyperactivity disorder","volume":"67","author":"Wilens TE","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115574493"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62021-1"},{"key":"e_1_2_8_116_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2014.898771"},{"key":"e_1_2_8_117_1","unstructured":"ZandB(2016).My 'smart drugs' nightmare. BBC. Available at:http:\/\/www.bbc.co.uk\/news\/magazine\u201035091574(accessed 5\/1\/17)."},{"key":"e_1_2_8_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.08.015"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbph.13813","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bph.13813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T03:25:26Z","timestamp":1694316326000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bph.13813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":117,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/bph.13813"],"URL":"https:\/\/doi.org\/10.1111\/bph.13813","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,12]]},"assertion":[{"value":"2017-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}